Atavistik Bio, a biotechnology company dedicated to accelerating the discovery and development of transformative precision allosteric therapeutics, has announced it has secured $120.0 million in new funding. This substantial investment round is poised to significantly bolster the company's ongoing efforts to address serious unmet patient needs, with a primary focus on oncology.
Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics. These therapies are designed to achieve superior efficacy and tolerability profiles by leveraging the power of allostery, a mechanism that modulates protein function at a site distinct from the active site. The company's lead candidate, ATV-1601, a selective allosteric inhibitor for solid tumors, is anticipated to enter clinical trials in early 2025.
The newly raised capital will be strategically deployed to advance Atavistik Bio's pipeline, further develop its proprietary platform, and support the clinical progression of ATV-1601. The company is led by an experienced team of drug hunters with a proven track record in developing marketed small molecule therapies. Atavistik Bio is supported by top-tier investors, including The Column Group, Nextech Invest, and Lux Capital, who have backed its mission to bring innovative treatments to patients.
This latest funding round underscores strong investor confidence in Atavistik Bio's innovative scientific approach and its potential to deliver transformative precision medicines to patients. The company remains steadfast in its commitment to expanding its therapeutic pipeline and advancing its promising candidates through rigorous development, ultimately aiming to address critical patient needs and improve treatment outcomes in oncology and other challenging disease areas.
